ALPN
$7.63
Alpine Immune Sciences
($.22)
(2.80%)
ALPN
Earnings Whisper ®
N/A
4th Quarter December 2022
Consensus:  ($0.27)
Revenue:  $10.96 Mil
Monday
Feb 13
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ALPN reports earnings?
Beat
Meet
Miss

Where is ALPN's stock price going from here?
Up
Flat
Down
Stock chart of ALPN
Analysts
Summary of analysts' recommendations for ALPN
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington.